Alphatec Holdings, Inc. $ATEC Stake Trimmed by Jump Financial LLC

Key Points

• Jump Financial LLC significantly reduced its holdings in Alphatec Holdings, Inc., selling 5,865,895 shares, which resulted in a 96.7% decrease in their position.
• Alphatec Holdings reported a quarterly earnings result with an EPS of $0.02, exceeding expectations and reflecting a revenue increase of 27.5% compared to the previous year.
• Multiple research firms have set optimistic price targets for Alphatec, with several analysts rating the stock as a "buy" and an average target price of $18.50.

Jump Financial LLC reduced its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 96.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 203,284 shares of the medical technology company's stock after selling 5,865,895 shares during the quarter. Jump Financial LLC owned about 0.14% of Alphatec worth $2,061,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Comerica Bank increased its stake in shares of Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after buying an additional 1,248 shares during the period. Quarry LP lifted its holdings in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after purchasing an additional 2,375 shares in the last quarter. Larson Financial Group LLC purchased a new stake in shares of Alphatec during the first quarter worth $54,000. Lazard Asset Management LLC purchased a new stake in shares of Alphatec in the fourth quarter valued at about $76,000. Finally, State of Wyoming purchased a new position in Alphatec during the fourth quarter worth about $86,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ATEC shares. Wall Street Zen lowered shares of Alphatec from a "buy" rating to a "hold" rating in a report on Saturday. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a research note on Monday, June 16th. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price objective on shares of Alphatec in a report on Friday, August 1st. Finally, Barclays reiterated an "overweight" rating and set a $22.00 price target (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $18.50.

Alphatec Stock Performance

Shares of ATEC traded down $0.13 during mid-day trading on Monday, hitting $15.90. 1,651,222 shares of the company's stock were exchanged, compared to its average volume of 2,698,129. The firm has a market capitalization of $2.35 billion, a P/E ratio of -14.07 and a beta of 1.02. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $16.47. The business's 50 day moving average is $12.88 and its two-hundred day moving average is $11.74. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The business's revenue was up 27.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, equities analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Insider Transactions at Alphatec

In other Alphatec news, General Counsel Tyson Eliot Marshall sold 18,092 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total transaction of $269,751.72. Following the sale, the general counsel owned 438,331 shares in the company, valued at $6,535,515.21. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Scott Lish sold 6,323 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $16.01, for a total value of $101,231.23. Following the sale, the chief operating officer directly owned 658,707 shares in the company, valued at approximately $10,545,899.07. This represents a 0.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 410,247 shares of company stock worth $5,376,804 over the last quarter. 22.80% of the stock is currently owned by insiders.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.